Business Context and Reporting Period
This Form 8-K was filed by Akerna Corp. on March 16, 2021, reporting events occurring primarily on March 10, 2021. The filing entity is Akerna Corp.; the provided company metadata identifies American Bitcoin Corp., which does not match the registrant named in the filing.
Key Financial and Capitalization Matters
- Akerna agreed to acquire 100% of Viridian Sciences, Inc. from Navigator Acquisition Corp. for 1,000,000 shares of Akerna common stock valued at $6.00 per share, implying stated consideration of $6.0 million.
- Up to an additional $1.0 million in Akerna common stock may be payable after the one-year period following closing, subject to specified revenue achievements.
- Of the acquisition share consideration, 100,000 shares valued at $6.00 per share, or $600,000, were to be deposited into escrow for working-capital adjustments and indemnification obligations.
- From February 11 through March 10, 2021, Akerna issued 1,113,969 common shares to convertible-note holders upon conversion of installment amounts due under the notes.
- The filing does not provide revenue, profit, cash-flow, margin, debt-balance, cash-balance, or liquidity figures.
Material Changes Versus the Prior Comparable Period
- The filing does not present period-over-period operating results.
- Material reported changes include the proposed acquisition of Viridian and the issuance of 1,113,969 shares through convertible-note conversions, resulting in potential or actual equity dilution.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Closing of the Viridian transaction was expected on or around April 1, 2021, subject to customary closing conditions; the filing does not confirm that closing occurred.
- The contingent acquisition consideration depends on achievement of revenue targets specified in the agreement.
- Escrowed shares may be used to satisfy net-working-capital adjustments and seller indemnification obligations.
- The agreement includes customary representations, warranties, covenants, post-closing indemnification provisions, and a one-year seller non-compete.
- The securities issued in the note conversions and the acquisition were issued under exemptions from Securities Act registration, including Section 3(a)(9), Rule 506(b), and/or Section 4(a)(2).
- Akerna established May 27, 2021 as the date of its annual stockholders meeting, with a record date of April 9, 2021. The filing set March 26, 2021 as the deadline for specified stockholder proposals and director nominations.
Investor Verification Checklist
- Verify whether the Viridian acquisition closed and review the final purchase accounting and consideration issued.
- Review the agreement’s revenue targets and determine whether contingent shares became payable.
- Assess the impact of the 1,113,969 note-conversion shares and the 1,000,000 acquisition shares on total shares outstanding and dilution.
- Confirm the treatment and release conditions for the 100,000 escrowed shares.
- Review subsequent filings for updated liquidity, debt, operating results, and any changes to the transaction terms.